With 2.27 million shares changed hands, the volume of the stock remained heavier than its average volume of 1.2 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $61.63 whereas the lowest price it dropped to was $59.18. The 52-week range on VRNA shows that it touched its highest point at $60.81 and its lowest point at $11.39 during that stretch. It currently has a 1-year price target of $64.22. Beta for the stock currently stands at 0.42.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of VRNA was up-trending over the past week, with a rise of 11.93%, but this was up by 31.72% over a month. Three-month performance surged to 75.44% while six-month performance rose 204.41%. The stock gained 235.17% in the past year, while it has gained 32.15% so far this year. A look at the trailing 12-month EPS for VRNA yields -1.94 with Next year EPS estimates of 0.04. For the next quarter, that number is -0.07. This implies an EPS growth rate of -177.78% for this year and 117.33% for next year.
Float and Shares Shorts:
At present, 81.83 million VRNA shares are outstanding with a float of 68.91 million shares on hand for trading. On 2025-01-15, short shares totaled 8.22 million, which was 1005.0000000000001 higher than short shares on 1734048000. In addition to Dr. David S. Zaccardelli Pharm.D. as the firm’s President, CEO & Executive Director, Mr. Mark W. Hahn serves as its Chief Financial Officer.
Institutional Ownership:
Through their ownership of 0.87036 of VRNA’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, VRNA reported revenue of $5624000.0 and operating income of -$39055000.0. The EBITDA in the recently reported quarter was -$34039000.0 and diluted EPS was -$0.56.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for VRNA since 7 analysts follow the stock currently. There are 7 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With VRNA analysts setting a high price target of 77.0 and a low target of 44.0, the average target price over the next 12 months is 65.75. Based on these targets, VRNA could surge 25.47% to reach the target high and fall by -28.3% to reach the target low. Reaching the average price target will result in a growth of 7.14% from current levels.
Analysts have provided yearly estimates in a range of -$0.1885 being high and -$0.22128 being low. For VRNA, this leads to a yearly average estimate of -$0.19977. Based on analyst estimates, the high estimate for the next quarter is -$0.01 and the low estimate is -$0.15. The average estimate for the next quarter is thus -$0.07.
